Pharmafile Logo

Research Partnership’s MedTech Division appoints two Directors

May 14, 2021 | Medtech, News, Staff announcement 

Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

We are delighted to announce that Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

Chris has over 27 years’ experience in healthcare research and consulting and his peers acknowledge him to be a strategic thinker with a demonstrated ability to leverage primary and secondary market research, connecting disparate pieces of information to form a clear picture. He most recently served as Vice President, Strategic Research Services for the KJT Group and his other professional experiences include roles with a product design consultancy, independent moderating, Becton Dickinson and with J&J’s Ethicon Endo-Surgery.

Andrew is a seasoned market research professional with over 13 years’ experience in healthcare research and consulting. He has experience of working across a broad range of therapy areas and devices and has previously focused on both quantitative and qualitative research. Andrew has previously worked at InStar Research and Medex Research.

Head of MedTech Division, Sabera Hyderally said of the appointment, “I am delighted to welcome both Chris and Andrew to the MedTech division. They bring a wealth of experience, deep knowledge and fresh ideas and I’m excited to partner with researchers of their calibre as we continue our tremendous growth globally.”

Founding Director Mary Assimakopoulos added, “We are very pleased that both Chris and Andrew have chosen to join Research Partnership. They have both previously worked with a range of MedTech clients and bring a great depth of experience to the team, which aims to stay at the forefront of best practice and innovation.”

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Exploring MINT: Part 4 – Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in...

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.